To this end, preclinical and clinical studies have focused on the inhibition of the RAS/MEK/ERK and PI3K/AKT/mTOR pathways, which play a crucial role in MPNST tumorigenesis and progression, although these trials have resulted in minimal clinical benefit [2,6,8]. Here, MAP2K7 is linked to malignant peripheral nerve sheath tumor.